交银国际:下调金斯瑞生物(01548.HK)2025年净利预测 维持“买入”评级

智通财经
Yesterday
【交银国际:下调金斯瑞生物(01548.HK)2025年净利预测 维持“买入”评级】智通财经APP获悉,交银国际发布研报称,上调金斯瑞生物科技(01548.HK)2025-27年收入1-5%,但考虑到2025年上半年传奇生物账面净亏损仍较大,下调2025年净利润预测。该行将SOTP模型滚动至2026年,各业务板块目标估值倍数保持不变,维持目标价28.75港元及“买入”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10